Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death.
Virard F, Giraud S, Bonnet M, Magadoux L, Martin L, Pham TH, Skafi N, Deneuve S, Frem R, Villoutreix BO, Sleiman NH, Reboulet J, Merabet S, Chaptal V, Chaveroux C, Hussein N, Aznar N, Fenouil T, Treilleux I, Saintigny P, Ansieau S, Manié S, Lebecque S, Renno T, Coste I.
Virard F, et al. Among authors: hussein n.
Nat Commun. 2024 Aug 15;15(1):7037. doi: 10.1038/s41467-024-51275-z.
Nat Commun. 2024.
PMID: 39147750
Free PMC article.